The genetics of migraine: implication for treatment approaches

  • M. D. Ferrari
  • J. Haan
Conference paper


Migraine is a paroxysmal neurological disorder affecting up to 12% of males and 24% of females in the general population, demonstrated to have a strong, but complex, genetic component. Genetic investigation of migraine bears great promise in providing new targets for drug development and optimization of individual specific therapy. Better, preferably prophylactic, treatment of migraine patients is desired because the presently used drugs are not effective in all patients, allow recurrence of the headache in a high percentage of patients and sometimes have severe adverse side effects. With the recent identification of the brain-specific P/Q-type calcium channel gene CACNA1A in the pathogenesis of migraine, the first step has been taken to identify primary biochemical pathways leading to migraine. Here, we summarize the current knowledge about the genetics of migraine and focus on the implication for treatment approaches.


Migraine Attack Essential Tremor Migraine Patient Migraine With Aura Ergot Alkaloid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bayliss DA, Li YW, Talley EM (1997) Effects of serotonin on caudal raphe neurons: inhibition of N-and P/Q-type calcium channels and the after hyperpolarization. J Neurophysiol 77: 1362–1374PubMedGoogle Scholar
  2. Bezanilla F (2000) The voltage sensor in voltage-dependent ion channels. Physiol Rev 80: 555–592PubMedGoogle Scholar
  3. Bito H (1998) The role of calcium in activity-dependent neuronal gene regulation. Cell Calcium 23: 143–150PubMedCrossRefGoogle Scholar
  4. Bourinet E, Soong TW, Sutton K, Slaymaker S, Mathews E, Monteil A, Zamponi GW, Nargeot J, Snutch TP (1999) Splicing of alpha 1A subunit gene generates phenotypic variants of P-and Q-type calcium channels. Nature Neurosci 2: 407–415PubMedCrossRefGoogle Scholar
  5. Brüss M, Bönisch H, Bühlen, Nöthen MM, Propping P, Göthert M (1999) Modified ligand binding to the naturally occurring Cys 124 variant of the human serotonin 5-HT1B receptor. Pharmacogenetics 9: 95–102PubMedGoogle Scholar
  6. Caddick SJ, Wang C, Fletcher CF, Jenkins NA, Copeland NG, Hosford DA (1999) Excitatory but not inhibitory synaptic transmission is reduced in lethargic (Cacnb4(lh)) and tottering (Cacnalatg) mouse thalami. J Neurophysiol 81: 2066–2074PubMedGoogle Scholar
  7. Catterall WA (1999) Interactions of presynaptic Ca2+ channels and snare proteins in neurotransmitter release. Ann NY Acad Sci 868: 144–159PubMedCrossRefGoogle Scholar
  8. Del Zompo M, Cherchi A, Palmas MA, Ponti M, Bocchetta A, Gessa GL, Piccardi MP (1998) Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology 51: 781–786PubMedCrossRefGoogle Scholar
  9. Dichgans M, Forderreuther S, Deiterich M, Pfaffenrath V, Gasser T (1998) The D2 receptor Ncol allele: absence of allelic association with migraine with aura. Neurology 51: 928PubMedCrossRefGoogle Scholar
  10. Diener HC, Kaube H, Limmroth V (1998) A practical guide to the management and prevention of migraine. Drugs 56: 811–824PubMedCrossRefGoogle Scholar
  11. Doyle J, Ren X, Lennon G, Stubbs L (1997) Mutations in the Cacnlla4 calcium channel gene are associated with seizures, cerebellar degeneration, and ataxia in tottering and leaner mutant mice. Mamm Genome 8: 113–120PubMedCrossRefGoogle Scholar
  12. Ducros A, Joutel A, Vahedi K, Cecillon M, Ferreira A, Bernard E, Verier A, Echenne B, Lopez de Munain A, Bousser MG, Tournier-Lasserve E (1997) Mapping of a second locus for familial hemiplegic migraine to Iq21-q23 and evidence of further heterogeneity. Ann Neurol 42: 885–890PubMedCrossRefGoogle Scholar
  13. Ducros A, Denier C, Joutel A, Vahedi K, Bousser M-G, Tournier-Lasserve E (1999) Characterization of CACNA1A mutations in familial and sporadic hemiplegic migraine. Neurology 52 [Suppl 2]: A273–274CrossRefGoogle Scholar
  14. Ducros A, Denier C, Joutel A, Vahedi K, Michel A, Darcel F, Madigand M, Guerouaou D, Tison F, Julien J, Hirsch E, Chedru F, Bisgard C, Lucotte G, Despres P, Billard C, Barthez MA, Ponsot G, Bousser MG, Tournier-Lasserve E (1999) Recurrence of the T666M calcium channel CACNA1A gene mutation in familial hemiplegic migraine with progressive cerebellar ataxia. Am J Hum Genet 64: 89–98PubMedCrossRefGoogle Scholar
  15. Ducros A, Denier C, Joutel A, et al. (2001) The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med 345:17–24PubMedCrossRefGoogle Scholar
  16. Elliott MA, Peroutka SJ, Welch S, May EF (1996) Familial hemiplegic migraine, nystagmus, and cerebellar atrophy Ann Neurol 39: 100–106Google Scholar
  17. Ferrari MD (1998) Migraine. Lancet 351: 1043–1051PubMedCrossRefGoogle Scholar
  18. Ferrari MD, for the Subcutaneous Sumatriptan International Study Group (1991) Treatment of migraine attacks with sumatriptan. N Engl J Med 325: 316–321CrossRefGoogle Scholar
  19. Ferrari MD, Saxena PR (1993) Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci 14:129–133PubMedCrossRefGoogle Scholar
  20. Ferrari MD, Saxena PR (1995) 5-HT1 receptors in migraine pathophysiology and treatment. Eur J Neurol 2: 5–21CrossRefGoogle Scholar
  21. Ferrari MD, Odink J, Tapparelli C, Van Kempen GM, Pennings EJ, Bruyn GW (1989) Serotonin metabolism in migraine. Neurology 39: 1239–1242PubMedCrossRefGoogle Scholar
  22. Ferrari MD, Odink J, Bos KD, Malessy MJ, Bruyn GW (1990) Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 40: 1582–1586PubMedCrossRefGoogle Scholar
  23. Fletcher CF, Lutz CM, O’sullivan TN, Shaughnessy JD, Hawkes R, Frankel WN, Copeland NG, Jenkins NA (1996) Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 87: 607–617PubMedCrossRefGoogle Scholar
  24. Fletcher CF, Tottene A, Lennon VA, Wilson SM, Dubel SJ, Paylor R, Hosford DA, Tessarollo L, McEnery MW, Pietrobon D, Copeland NG, Jenkins NA (2001) Dystonia and cerebellar atrophy in Cacnala null mice lacking P/Q calcium channel activity. FASEB J 15:1288–1290PubMedGoogle Scholar
  25. Gardner K, Barmada MM, Ptacek LJ, Hoffman EP (1997) A new locus for hemiplegic migraine maps to chromosome lq31. Neurology 49: 1231–1238PubMedCrossRefGoogle Scholar
  26. Goadsby PJ (1997) How do the currently used prophylactic agents work in migraine? Cephalalgia 17: 85–92PubMedCrossRefGoogle Scholar
  27. Goldstein J, Hoffman HD, Armellino JJ, Battikha JP, Hamelsky SW, Couch J, Blumenthal H, Lipton RB (1999) Treatment of severe, disabling migraine attacks in over-the-counter population of migraine sufferers: results from three randomized, placebo-controlled studies of the combination of acetaminophen, aspirin, and caffeine. Cephalalgia 19: 684–691PubMedCrossRefGoogle Scholar
  28. Haan J, Terwindt GM, Ferrari MD (1997) Genetics of migraine. In: Mathew NT (ed) Neurological clinics. Saunders, Philadelphia, pp 43–60 (Adv Headache)Google Scholar
  29. Hans M, Luvisetto S, Williams ME, Spagnolo M, Urrutia A, Tottene A, Brust PF, Johnson EC, Harpold MM, Stauderman KA, Pietrobon D (1999) Functional consequences of mutations in the human a lA calcium channel subunit linked to familial hemiplegic migraine. J Neurosci 9: 1610–1619Google Scholar
  30. Headache Classification Committee of the International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8: 1–97CrossRefGoogle Scholar
  31. Heng JE, Zurakowski D, Vorwerk CK, Grosskreutz CL, Dreyer EB (1999) Cation channel control of neurite morphology. Dev Brain Res 113: 67–73CrossRefGoogle Scholar
  32. Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET (1990) Serotonin and migraine. Ann NY Acad Sci 600: 587–600PubMedCrossRefGoogle Scholar
  33. Joutel A, Bousser MG, Biousse V, Labauge P, Chabriat H, Nibbio A, Maciazek J, Meyer B, Bach MA, Weissenbach J, Latrop GM, Tournier-Lasserve E (1993) A gene for familial hemiplegic migraine maps to chromosome 19. Nat Genet 5: 40–45PubMedCrossRefGoogle Scholar
  34. Jun K, Piedras-Renteria ES, Smith SM, Wheeler DB, Lee SB, Lee TG, Chin H, Adams ME, Scheller RH, Tsien RW, Shin HS (1999) Ablation of P/Q-type Ca(2+) channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the alpha(1A)-subunit. Proc Natl Acad Sci USA 96: 15245–15250PubMedCrossRefGoogle Scholar
  35. Kraus RL, Sinnegger MJ, Glossmann H, Hering S, Striessnig J (1998) Familial hemiplegic migraine mutations change a 1A Ca2+ channel kinetics. J Biol Chem 273: 5586–5590PubMedCrossRefGoogle Scholar
  36. Kraus RL, Sinnegger MJ, Koschak A, Glossmann H, Stenirri S, Carrera P, Striessnig J (2000) Three new familial hemiplegic migraine mutants affect P/Q-type Ca(2+) channel kinetics. J Biol Chem 275: 9239–9243PubMedCrossRefGoogle Scholar
  37. Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu D-H, Virkkunen M, Weight F, Linnoila M, Goldman D (1995) Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2C receptor gene (HTR2C). Genomics 2: 274–279CrossRefGoogle Scholar
  38. Launer LJ, Terwindt GM, Ferrari MD (1999) The prevalence and characteristics of migraine in a population based cohort: the GEM study. Neurology 53: 537–542PubMedCrossRefGoogle Scholar
  39. Lee A, Wong ST, Gallagher D, Li B, Storm DR, Scheuer T, Catterall WA (1999) Ca2+/calmodulin binds to and modulates P/Q-type calcium channels. Nature 399:155–159PubMedCrossRefGoogle Scholar
  40. Lipton RB, Stewart WF, Ryan RE Jr, Saper J, Silberstein S, Sheftell F (1998) Efficacy and safety of randomized, placebo-controlled trials. Arch Neurol 55: 210–217PubMedCrossRefGoogle Scholar
  41. MaassenVanDenBrink A, Vergouwe MN, Ophoff RA, Saxena PR, Ferrari MD, Frants RR (1998) 5-HTi B receptor polymorphisms and clinical response to sumatriptan. Headache 38: 288–291CrossRefGoogle Scholar
  42. MaassenVanDenBrink A, Bax WA, Ramrattan NN, Ferrari MD, Saxena PR (1999) Human coronary artery contraction to sumatriptan: a post hoc analysis. Cephalalgia 9: 651–654CrossRefGoogle Scholar
  43. Maximov A, Sudhof TC, Bezprozvanny I (1999) Association of neuronal calcium channels with modular adaptor proteins. J Biol Chem 274: 24453–24456PubMedCrossRefGoogle Scholar
  44. McCarthy JJ, Hilfiker R (2000) The use of single-nucleotide polymorphism maps in harmacogenomics. Nature Biotech 8: 505–508CrossRefGoogle Scholar
  45. Meyler WJ (1996) Side effects of ergotamine. Cephalalgia 16: 5–10PubMedCrossRefGoogle Scholar
  46. Montagna P (2000) Molecular genetics of migraine headaches: a review. Cephalalgia 20: 3–14PubMedCrossRefGoogle Scholar
  47. Mori Y, Wakamori M, Oda S, Fletcher CF, Sekiguchi N, Mori E, Copeland NG, Jenkins NA, Matsushita K, Matsuyama Z, Imoto K (2000) Reduced voltage sensitivity of activation of P/Q-type Ca2+ channels is associated with the ataxic mouse mutation rolling Nagoya (tg(rol)). J Neurosci 20: 5654–5662PubMedGoogle Scholar
  48. Ophoff RA, van Eijk R, Sandkuijl LA, Terwindt GM, Grubben CP, Haan J, Lindhout D, Ferrari MD, Frants RR (1994) Genetic heterogeneity of familial hemiplegic migraine. Genomics 22: 21–26PubMedCrossRefGoogle Scholar
  49. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, Lamerdin JE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GJ, Hofker MH, Ferrari MD, Frants RR (1996) Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87: 543–552PubMedCrossRefGoogle Scholar
  50. Peroutka SJ (1997) Dopamine and migraine. Neurology 49: 650–656PubMedCrossRefGoogle Scholar
  51. Peroutka SJ, Wilhoit T, Jones K (1997) Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) Ncol alleles. Neurology 49: 201–206PubMedCrossRefGoogle Scholar
  52. Plomp J. J, Vergouwe MN, Van den Maagdenberg AM, Ferrari MD, Frants RR, Molenaar PC (2000) Abnormal transmitter release at neuromuscular junctions of mice carrying the tottering α(1A) Ca(2+) channel mutation. Brain 123(Pt 3): 463–471PubMedCrossRefGoogle Scholar
  53. Qian J, Noebels JL (2000) Presynaptic Ca(2+) influx at a mouse central synapse with Ca(2+) channel subunit mutations. J Neurosci 20: 163–170PubMedGoogle Scholar
  54. Russell MB, Olesen J (1996) A nosographic analysis of the migraine aura in a general population. Brain 119: 355–361PubMedCrossRefGoogle Scholar
  55. Russell MB, Iselius L, Olesen J (1995) Inheritance of migraine investigated by complex segregation analysis. Hum Genet 96: 726–730PubMedCrossRefGoogle Scholar
  56. Silberstein SD (1998) Methysergide. Cephalalgia 8: 421–435CrossRefGoogle Scholar
  57. Stewart WF, Lipton RB, Celentano DD, Reed ML (1992) Prevalence of migraine headache in the United States: relation to age, income, race and other sociodemographic factors. J Am Med Assoc 267: 64–69CrossRefGoogle Scholar
  58. Sudhof TC (1995) The synaptic vesicle cycle: a cascade of protein-protein interactions. Nature 375: 645–653PubMedCrossRefGoogle Scholar
  59. Terwindt GM, Ophoff RA, Haan J, Vergouwe MN, van Eijk R, Frants RR, Ferrari MD (1998) Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine. Dutch Migraine Genetics Research Group. Neurology 50: 1105–1110PubMedCrossRefGoogle Scholar
  60. Tfelt-Hansen P, Paalzow L (1985) Intramuscular ergotamine: plasma levels and dynamic activity. Clin Pharmacol Ther 37: 29–35PubMedCrossRefGoogle Scholar
  61. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G (1995) The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 346: 923–926PubMedCrossRefGoogle Scholar
  62. Toda N, Tfelt-Hansen P (2000) Calcium antagonists in migraine prophylaxis. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds) The headaches, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 477–487Google Scholar
  63. Visser WH, Jaspers NMWH, Vriend de RHM, Ferrari MD (1996) Chest symptoms after sumatriptan: a two-years clinical practice review in 735 consecutive migraine patients. Cephalalgia 16: 554–559PubMedCrossRefGoogle Scholar
  64. Westenbroek RE, Sakurai T, Elliott EM, Hell JW, Starr TV, Snutch TP, Catterall WA (1995) Immunochemical identification and subcellular distribution of the alpha 1A subunits of brain calcium channels. J Neurosci 15: 6403–6418PubMedGoogle Scholar
  65. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, Dobyns WB, Subramony SH, Zoghbi HY, Lee CC (1997) Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha lA-voltagedependent calcium channel. Nat Genet 15: 62–69PubMedCrossRefGoogle Scholar
  66. Zwingman TA, Neumann PE, Noebels JL, Herrup K (2001) Rocker is a new variant of the voltage-dependent calcium channel gene Cacnala. J Neurosci 21: 1169–1178PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2002

Authors and Affiliations

  • M. D. Ferrari
    • 1
  • J. Haan
    • 1
    • 2
  1. 1.Department of NeurolgyLeiden University Medical CenterLeidenThe Netherlands
  2. 2.Department of NeurologyRijnland Hospital LeiderdorpThe Netherlands

Personalised recommendations